文献速递中药与中成药合理使用中医内科

加味阳和汤经JAK2/STAT3通路调节免疫抑制乳腺癌

Jiawei Yanghe Decoction suppresses breast cancer by regulating immune responses via JAK2/STAT3 signaling pathway.
PubMed 文献 · J Ethnopharmacol · 2023-03-17

本研究围绕加味阳和汤(JWYHD)的抗乳腺癌作用及机制,采用原位异种移植乳腺癌小鼠模型、斑马鱼炎症模型、RAW 264.7细胞及网络药理学,并结合Western blot、RT-PCR、IHC、ELISA验证。结果显示JWYHD呈剂量依赖性抑制肿瘤生长,减少M2巨噬细胞与Treg、增加M1巨噬细胞,降低IL-1β、IL-6、TNFα、PTGS2、VEGFα并诱导凋亡,且抑制JAK2/STAT3通路,Colivelin可逆转该抑制作用。

要点

  • JWYHD呈剂量依赖性抑制原位乳腺癌小鼠模型的肿瘤生长。
  • JWYHD调节免疫并降低IL-1β、IL-6、TNFα、PTGS2、VEGFα,诱导凋亡。
  • JWYHD经抑制JAK2/STAT3通路发挥作用,Colivelin可逆转其体外效应。

核心结论

  • 加味阳和汤主要通过抑制炎症、激活免疫反应并经JAK2/STAT3信号通路诱导凋亡,发挥显著抗肿瘤作用,为临床应用提供药理学证据。

研究设计与样本

  • 采用原位异种移植乳腺癌小鼠模型与斑马鱼炎症模型观察抗肿瘤及免疫细胞调节作用。
  • 以LPS诱导的RAW 264.7细胞评价抗炎作用,并用UPLC-MS/MS鉴定成分、网络药理学筛选靶点。
  • 通过Western blot、RT-PCR、IHC、ELISA验证靶点与通路,并用Colivelin与Stattic探讨JAK2/STAT3通路作用。

主要发现

  • JWYHD在原位异种移植乳腺癌小鼠模型中呈剂量依赖性降低肿瘤生长。
  • 流式细胞术与IHC显示JWYHD减少M2巨噬细胞与Treg表达、增加M1巨噬细胞。
  • ELISA与Western blot显示JWYHD组肿瘤组织中IL-1β、IL-6、TNFα、PTGS2、VEGFα降低,并在RAW264.7细胞与斑马鱼炎症模型中得到验证。
  • TUNEL与IHC显示JWYHD显著诱导凋亡,IHC与Western blot显示其降低JAK2/STAT3通路表达,Colivelin可逆转其体外降低效应。

关键数值与推荐

  • JWYHD抑制TNFα、PTGS2、EGFR、STAT3、VEGFα的表达。

临床怎么用

  • 可将JWYHD作为乳腺癌辅助治疗的候选方剂,重点关注其免疫调节与JAK2/STAT3通路抑制作用。
  • 临床联合用药或疗效评估时可关注M1/M2巨噬细胞、Treg及IL-1β、IL-6、TNFα、PTGS2、VEGFα等指标变化。

局限性

  • 研究以细胞、斑马鱼与小鼠模型为主,尚缺乏临床人体试验证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: Jiawei Yanghe Decoction (JWYHD) is a widely used traditional Chinese medicine prescription in the clinical setting for the treatment of autoimmune diseases. Many studies showed that JWYHD has anti-tumor activities in cell and animal models. However, the anti-breast cancer effects of JWYHD and the underlying mechanisms of action remain unknown. AIM OF STUDY: This study aimed to determine the anti-breast cancer effect and reveal the underlying mechanisms of action in vivo, in vitro and in silico. MATERIALS AND METHODS: Orthotopic xenograft breast cancer mouse model and inflammatory zebrafish model were used to observe the anti-tumor effect and immune cell regulation of JWYHD. Moreover, the anti-inflammatory effect of JWYHD were evaluated by the expression of RAW 264.7 cells. JWYHD active ingredients were obtained by UPLC-MS/MS and potential targets were screened by network pharmacology. The therapeutic targets and signaling pathways predicted by computer were assessed by Western blot, real-time PCR (RT-PCR), immunohistochemistry (IHC) staining, and Enzyme-linked immunosorbent assays (ELISA) to explore the therapeutic mechanism of JWYHD against breast cancer. At last, Colivelin and Stattic were used to explore the effect of JWYHD on JAK2/STAT3 pathway. RESULTS: JWYHD significantly decreased the tumor growth in a dose-dependent manner in the orthotopic xenograft breast cancer mouse model. Flow cytometry and IHC results indicated that JWYHD decreased the expressions of M2 macrophages and Treg while increasing M1 macrophages. Meanwhile, ELISA and Western blot results showed a decrease in IL-1β, IL-6, TNFα, PTGS2 and VEGFα in tumor tissue of JWYHD groups. The results were also verified in LPS-induced RAW264.7 cells and zebrafish inflammatory models. TUNEL assay and IHC results showed that JWYHD significantly induced apoptosis. Seventy-two major compounds in JWYHD were identified by UPLC-MS/MS and Network pharmacology. It was found that the significant binding affinity of JWYHD to TNFα, PTGS2, EGFR, STAT3, VEGFα and their expressions were inhibited by JWYHD. IHC and Western blot analysis showed that JWYHD could decrease the expression of JAK2/STAT3 pathway. Furthermore, Colivelin could reverse the decrease effect of JWYHD in vitro. CONCLUSION: JWYHD exerts a significant anti-tumor effect mainly by inhibiting inflammation, activating immune responses and inducing apoptosis via the JAK2/STAT3 signaling pathway. Our findings provide strong pharmacological evidence for the clinical application of JWYHD in the management of breast cancer.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. You Y, Chen X, Chen X, et al. Jiawei Yanghe Decoction suppresses breast cancer by regulating immune responses via JAK2/STAT3 signaling pathway. J Ethnopharmacol. 2023. PMID: 36933872. doi:10.1016/j.jep.2023.116358

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。